GMI 1271

Drug Profile

GMI 1271

Alternative Names: GMI-1271

Latest Information Update: 29 May 2017

Price : $50

At a glance

  • Originator GlycoMimetics
  • Class Antineoplastics; Antithrombotics; Glycolipids; Small molecules
  • Mechanism of Action E-selectin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute myeloid leukaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Acute myeloid leukaemia
  • Phase I/II Deep vein thrombosis
  • Phase I Multiple myeloma; Stem cell mobilisation
  • Preclinical Chronic myeloid leukaemia; Solid tumours

Most Recent Events

  • 25 May 2017 GMI 1271 receives Orphan Drug status for Acute myeloid leukaemia in European Union
  • 22 May 2017 GlycoMimetics plans a phase III trial for Acute myeloid leukaemia (Second-line therapy)
  • 17 May 2017 GMI 1271 receives Breakthrough Therapy status for Acute myeloid leukaemia (Second-line therapy or greater) in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top